SynthesisHead & neck2026
Prognostic Impact of Anterior Commissure Involvement on Treatment Failure in Early-Stage Glottic Carcinoma Treated With Definitive Radiotherapy: A Univariate and Multivariate Meta-Analysis.
Synthesis in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-stage glottic carcinoma is characterized by high cure rate, but about 10% of patients still develop local recurrence after radiotherapy (RT). Although advances in local therapies have markedly improved larynx preservation, anterior commissure involvement (ACI) may worsen outcomes yet remains insufficient to fully guide personalized treatment. Here, we conducted a univariate meta-analysis and a Bayesian multivariate meta-analysis of multiple factors (MVMA-MF) to evaluate the prognostic impact of ACI and on local failure in early-stage glottic carcinoma.
methodsWe conducted a systematic review with univariate meta-analysis and MVMA-MF using data from studies of early-stage glottic carcinoma treated with definitive RT, incorporating clinical information, risk factors and survival outcomes. A systematic literature search was conducted in PubMed and Scopus on Sep 27, 2025. Eligible studies provided sufficient data to estimate odds ratios (ORs) for local control in relation to patient, tumor and treatment factors, including ACI. Data extraction followed PRISMA guidelines, and study quality was assessed using MINORS criteria. The primary endpoint of the study was the effect of ACI on local failure. Pooled ORs were calculated with a random-effects model, and heterogeneity was assessed using the Cochrane Q test and I
findingsNine clinical trials representing 2527 patients were included. In univariate meta-analysis, the presence of ACI was significantly associated with an increased risk of local recurrence in early-stage glottic carcinoma treated with RT (OR 1.61, 95% CI 1.15-2.26, p = 0.006), with moderate heterogeneity (I
interpretationThis study represents the first application of both univariate and multivariate meta-analysis to clarify the prognostic role of ACI in early-stage glottic carcinoma treated with definitive RT. While univariate analysis suggested ACI increased recurrence risk, this effect was not confirmed in MVMA-MF, indicating the univariate findings may be confounded by correlation with other factors, particularly T substage. MVMA-MF approach accounted for heterogeneity, collinearity and incomplete reporting, providing more robust evidence. This work underscores the value of advanced multivariate methods in oncology meta-analysis and provides the strongest evidence to date that ACI should not be regarded as a fundamental prognostic criterion in early-stage glottic carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.